QUC398

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Knee osteoarthritisOsteoarthritis, Knee

Phase 2

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

TerminatedNCT05462990

Novartis PharmaceuticalsOsteoarthritis, Knee

Start: 2022-11-09End: 2025-04-08Updated: 2026-03-31

A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptomatic knee osteoarthritis

CompletedCTIS2023-509274-28-00

Novartis Pharma AGKnee osteoarthritis

Start: 2023-02-03End: 2025-04-08Target: 76Updated: 2024-12-20